🇺🇸 Sodium Chloride Physiological Solution in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 14
Most-reported reactions
- Anaphylactic Shock — 2 reports (14.29%)
- Hypersensitivity — 2 reports (14.29%)
- Myelosuppression — 2 reports (14.29%)
- Rash — 2 reports (14.29%)
- Asthenia — 1 report (7.14%)
- Blood Pressure Increased — 1 report (7.14%)
- Chest Discomfort — 1 report (7.14%)
- Dyspnoea — 1 report (7.14%)
- Generalised Tonic-Clonic Seizure — 1 report (7.14%)
- Hypertension — 1 report (7.14%)
Other Supportive Care / Fluid and Electrolyte Management approved in United States
Frequently asked questions
Is Sodium Chloride Physiological Solution approved in United States?
Sodium Chloride Physiological Solution does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Sodium Chloride Physiological Solution in United States?
Shanghai Hengrui Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.